Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies - Trial NCT05239689
Access comprehensive clinical trial information for NCT05239689 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Zhejiang University and is currently Recruiting. The study focuses on AML. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang University
Timeline & Enrollment
Early Phase 1
Feb 28, 2022
Dec 05, 2024
Primary Outcome
Dose-limiting toxicity (DLT),Incidence of treatment-emergent adverse events (TEAEs)
Summary
Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of
 CD38-positive Hematological Malignancies
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05239689
Non-Device Trial